Category

NASDAQ

LEQEMBI(R) (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China NASDAQ

LEQEMBI(R) (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

LEQEMBI(R) (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease TOKYO and CAMBRIDGE, Mass., September 8, 2026 - (JCN Newswire) - Eisai Co., Ltd. and Biogen…
bubmag
September 8, 2026
The Campbell’s Company to Participate in a Fireside Chat at Barclays Global Consumer Staples Conference on September 9 NASDAQ

The Campbell’s Company to Participate in a Fireside Chat at Barclays Global Consumer Staples Conference on September 9

CAMDEN, N.J.--(BUSINESS WIRE)--Sep 4, 2026-- The Campbell’s Company (NASDAQ:CPB) today announced that Mick Beekhuizen, President and Chief Executive Officer, and Todd Cunfer, Executive Vice President and Chief Financial Officer, will participate in a fireside…Read More
bubmag
September 4, 2026